News

Public · Published

Corxel Secures $300 Million Private Investment to Go Public via Amanat Acquisition

Corxel Pharmaceuticals plans to go public by merging with blank-check company Amanat Acquisition. The deal includes an oversubscribed $300 million private investment from healthcare funds and is expected to provide $377 million in gross proceeds to fund operations through 2029.

Published:

Updated:

What happened

Corxel Pharmaceuticals plans to go public by merging with blank-check company Amanat Acquisition. The deal includes an oversubscribed $300 million private investment from healthcare funds and is expected to provide $377 million in gross proceeds to fund operations through 2029.

Confirmed

Global impact / market context

The cash lets Corxel fund global phase 3 trials of its once-daily oral obesity pill without relying on public markets right away. For Amanat shareholders, the deal turns a shell company into an obesity-drug developer with several years of funded operations.

Analyst inference

The raise by a clinical-stage obesity drugmaker signals investors still fund oral weight-loss treatments that could compete with injectable drugs. A merger with a blank-check company, which is a listed shell formed to buy a private business, is the chosen route to public markets.

Analyst inference

What to watch

  1. The transaction is expected to close in the first half of 2027, so the merger and the private investment face a long wait before completion. Confirmed
  2. Corxel plans global phase 3 trials of CX11, its once-daily GLP-1 pill, after alignment with the Food and Drug Administration, and a phase 1b study of higher doses should yield data in the first half of next year. Confirmed
  3. Only Corxel US and its obesity portfolio join Amanat; Corxel HK and JX10 stay private, so public investors get a narrower set of assets than the whole company. Analyst inference

Evidence

  • Original source link unavailable